- Investing Ideas
- German Pharmaceuticals & Biotech Pure Equity Growth
German Pharmaceuticals & Biotech Pure Equity Growth
Results
12
Companies that has zero debt on their balance sheet and is forecast to grow at an exponential rate in the future.
12 companies
Krystal Biotech
Market Cap: €9.5b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
4KB
€274.10
7D
5.3%
1Y
n/a
Krystal Biotech
Market Cap: €9.5b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
4KB
€281.60
7D
7.0%
1Y
136.9%
Corcept Therapeutics
Market Cap: €8.9b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
HTD
€71.22
7D
12.6%
1Y
17.4%
Camurus
Market Cap: €32.2b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
7CA
€48.46
7D
-1.5%
1Y
-12.7%
BioArctic
Market Cap: €26.8b
Develops biological drugs for patients with central nervous system disorders in Sweden.
B9A
€26.30
7D
-6.5%
1Y
46.7%
Bonesupport Holding
Market Cap: €15.0b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
2B4
€20.72
7D
-1.0%
1Y
-10.5%
Neuren Pharmaceuticals
Market Cap: €1.7b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NK9
€8.10
7D
0%
1Y
18.2%
Kuros Biosciences
Market Cap: €808.5m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
YTSN
€22.14
7D
3.1%
1Y
-17.8%
Clarity Pharmaceuticals
Market Cap: €800.4m
A clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.
1F4
€1.28
7D
-4.5%
1Y
n/a
BioPorto
Market Cap: €584.2m
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.
2P4
€0.14
7D
-11.7%
1Y
-18.5%
Marker Therapeutics
Market Cap: €24.3m
A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
GX1
€1.31
7D
0%
1Y
n/a
Marker Therapeutics
Market Cap: €22.8m
A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
GX1
€1.03
7D
-15.6%
1Y
-21.4%